Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 20;14(10):2516.
doi: 10.3390/cancers14102516.

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy

Vera Rentsch  1 , Katja Seipel  2 , Yara Banz  3 , Gertrud Wiedemann  4 , Naomi Porret  4 , Ulrike Bacher  5 , Thomas Pabst  1
Affiliations

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy

Vera Rentsch et al. Cancers (Basel). .

Abstract

Chimeric antigen receptor T-cells (CAR T) treatment has become a standard option for patients with diffuse large B-cell lymphomas (DLBCL), which are refractory or relapse after two prior lines of therapy. However, little evidence exists for treatment recommendations in patients who relapse after CAR T-cell treatment and the outcome for such patients is poor. In this study, we evaluated the safety and efficacy of a monotherapy with the bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy. The patients received a maximum of 12 cycles of glofitamab after a single obinutuzumab pre-treatment at an academic institution. CRS was observed in two patients (grade 2 in both patients). We observed an overall response rate of 67%, with four patients achieving a complete response and a partial remission in two patients. Interestingly, we identified increased persistence of circulating CAR T-cells in peripheral blood in three of the five patients with measurable CAR T-cells. Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.

Keywords: CAR T-cell therapy; diffuse large B-cell lymphoma (DLBCL); glofitamab; relapse.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. No financial support was received from Roche Pharma; data were analyzed and the manuscript was written completely independently from the company.

Figures

Figure 1
Figure 1
Peak IL-6 measurements of all treated patients during each cycle.
Figure 2
Figure 2
Swimmer plot illustrating outcomes after glofitamab therapy.
Figure 3
Figure 3
(a) Progression-free and (b) overall survival of all patients.
Figure 4
Figure 4
CAR T-cell expansion during glofitamab therapy. (a) CAR T-cell copies/mcg DNA in one patient who had CR and experienced a re-expansion of CAR T-cells after glofitamab; (b) median CAR T-cell copies/mcg DNA before and after glofitamab in all patients who had measurable CAR T-cells; (c) CAR T-cell copies/mcg DNA for each patient after the administration of glofitamab.
See this image and copyright information in PMC

References

    1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., et al. The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed
    1. International Non-Hodgkin’s Lymphoma Prognostic Factors Project A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. N. Engl. J. Med. 1993;329:987–994. doi: 10.1056/NEJM199309303291402. - DOI - PubMed
    1. Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., Klasa R., Savage K.J., Shenkier T., Sutherland J., et al. The Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood. 2007;109:1857–1861. doi: 10.1182/blood-2006-08-038257. - DOI - PubMed
    1. Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D.C., Trneny M., Bosly A., Ketterer N., Shpilberg O., Hagberg H., et al. Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. J. Clin. Oncol. 2010;28:4184–4190. doi: 10.1200/JCO.2010.28.1618. - DOI - PMC - PubMed
    1. Van Den Neste E., Schmitz N., Mounier N., Gill D., Linch D., Trneny M., Milpied N., Radford J., Ketterer N., Shpilberg O., et al. Outcome of Patients with Relapsed Diffuse Large B-Cell Lymphoma Who Fail Second-Line Salvage Regimens in the International CORAL Study. Bone Marrow Transpl. 2016;51:51–57. doi: 10.1038/bmt.2015.213. - DOI - PubMed